Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki), All indications
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
31
Last updated

All questions

Guidelines: Enhertu (fam-trastuzumab deruxtecan-nxki), all indications

1 question · 1 source

Guidelines

Which NCCN antiemetic regimens apply to highly emetogenic drugs such as Enhertu?

Note: The NCCN recommendation applies to all high emetic risk anticancer agents; the Enhertu HCP site applies it because the product is classified as highly emetogenic. The table columns are Days 1 to 4; the letters after drug names are footnote markers on the source page. The site's reference list gives an access date of April 3, 2026, for the NCCN Guidelines for Antiemesis V.1.2026.